Ebglyss: how long were the pivotal tox studies?

“Safety pharmacology parameters were included in the 6- and 39-week intravenous and/or 13-week subcutaneous repeat-dose toxicology studies in cynomolgus monkeys.”

“GLP-compliant repeat-dose studies of 6 weeks, 13 weeks and 9 months in duration were conducted in cynomolgus monkeys to evaluate the toxicity and TK of lebrikizumab.”

“Monkeys of different ages and maturity (1 to 4.5 years) were used, and IV and SC routes of administration were evaluated.”